<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898376</url>
  </required_header>
  <id_info>
    <org_study_id>2016-003518-28</org_study_id>
    <nct_id>NCT02898376</nct_id>
  </id_info>
  <brief_title>Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer</brief_title>
  <acronym>FIBROTHERME</acronym>
  <official_title>Evaluation of the Clinical Benefit of a Spa Care on the Evolution of Late Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Francaise pour la Recherche Thermale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the dermatological life quality six months after spa cares in patients
      with severe late toxicity involving the skin and / or soft tissues after postoperative
      radiotherapy for breast cancer. Half of the patients will be treated with a combination of
      pentoxifylline (PTX) and alpha-tocopherol (Vit E) when Half of the patients will receive
      skin-oriented spa cares in addition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of PTX and vit E appears as the standard treatment of radiation induced
      fibrosis. Synergism between PTX and Vit E is likely, as treatment with each drug alone is
      ineffective. This combination was also positively evaluated in the treatment of
      osteoradionecrosis, radiation-induced pelvic neuropathies, pneumoniae as well as bowel
      pathologies.

      Spa cares are part of the standard treatment of burn scars. Two spa treatments per year
      enable the mitigation or disappearance (after several treatments) of pruritus, dysesthesia,
      local inflammation, hypertrophy and sclerosis. They promote the healing of chronic
      superficial erosions. The spa treatment combines baths, sprays and especially filiform
      showers with thermal water jets under high pressure for a few minutes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dermatology Quality of life at 6 months</measure>
    <time_frame>6 months after the end of treatment</time_frame>
    <description>Self-reported dermatology quality of life using the standardized Dermatology Life Quality Index (DLQI) ; This score assess the functional impact of fibrosis: eg. intensity of pain, itching... (10 items). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Quality of life at 12 months</measure>
    <time_frame>12 months after the end of treatment</time_frame>
    <description>Self-reported dermatology quality of life using the standardized Dermatology Life Quality Index (DLQI) ; This score assess the functional impact of fibrosis: eg. intensity of pain, itching... (10 items). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>quality of life questionnaire (EORTC QLQ C30 score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast-oriented quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>EORTC QLQ-BR23 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late radiation toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of late toxicity performed independently and in blind by another radiation oncologist from the same center, using the CTCAE v4.0 scale modules: Skin and subcutaneous tissue disorders / Musculoskeletal skeletal / Reproductive organs and breast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin thickness</measure>
    <time_frame>6 months</time_frame>
    <description>The skin thickness will be assessed in blind by an independently radiologist using a standardized Ultrasound scan procedure (Yoshida EJ, et al; Int J Radiat Oncol Biol Phys. 2012) Skin thickness is measured as the distance between the entry ultrasound echo signal to the border between the dermis and hypodermis . Measurements are acquired from ten locations: five on the treated (irradiated) breast (12:00, 3:00, 6:00, 9:00, and tumor bed), and five corresponding locations on the untreated (contralateral) breast - serving as controls to account for patient baseline variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic appearance</measure>
    <time_frame>6 months</time_frame>
    <description>The cosmetic appearance will be evaluated by the investigator with the Harvard-breast-cosmesis-scale (HBCS). HBCS classifies the overall aesthetic results in four categories from excellent, good, fair to poor; comparing the treated breast to the control breast</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>combination tocopherol/pentoxifylline + spa care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination tocopherol/pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin-oriented spa care</intervention_name>
    <description>standardized procedure : 72 care sessions over 18 days of treatment
+/- Additional care according to the specificity of each spa</description>
    <arm_group_label>combination tocopherol/pentoxifylline + spa care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400 mg bid during at least 6 months</description>
    <arm_group_label>combination tocopherol/pentoxifylline + spa care</arm_group_label>
    <arm_group_label>combination tocopherol/pentoxifylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocopherol acetate</intervention_name>
    <description>500 mg bid during at least 6 months</description>
    <arm_group_label>combination tocopherol/pentoxifylline + spa care</arm_group_label>
    <arm_group_label>combination tocopherol/pentoxifylline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women

          -  age ≥ 18 and &lt;80 years old

          -  invasive or in situ breast carcinoma

          -  non-metastatic disease.

          -  postoperative radiotherapy completed since at least 6 months

          -  unilateral breast radiotherapy

          -  grade &gt; 2 dermal and/or soft tissue toxicity (CTCAE v4.0)

          -  no inflammatory ou infectious flare on the breast at the time of inclusion

          -  ability to provide an informed written consent form

          -  affiliation to a social security system

        Exclusion Criteria:

          -  age &lt;18 or ≥ 80 years old

          -  evolutive cancer

          -  Metastatic Disease

          -  Patient undergoing specific treatment for breast cancer (except adjuvant endocrine
             therapy and / or adjuvant Herceptin) at the time of inclusion

          -  bilateral Breast/chest wall Radiotherapy

          -  breast prosthesis bearer

          -  Body Mass Index &gt; 40 or &lt;18.5

          -  chronic skin ulceration within the treated breast at the time of inclusion

          -  contraindications to spa care :

               -  inflammatory disease in flare at the time of inclusion

               -  active infections

               -  heart failure (NYHA class&gt; 1)

               -  chronic respiratory failure

               -  labile blood pressure

               -  bullous dermatitis

          -  evolutive chronic skin disease

          -  hypersensitivity to pentoxifylline or any of the excipients

          -  acute myocardial infarction

          -  ongoing hemorrhage or major bleeding risk

          -  use of oral anticoagulants

          -  pregnant or likely to be in 6 months or breastfeeding

          -  patients deprived of liberty or under supervision
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VOGIN Guillaume, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN Jean Louis</last_name>
    <phone>0033383598307</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES Laurinda</last_name>
    <phone>0033383598487</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bontemps Patrick, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ONCODOC</name>
      <address>
        <city>Béziers</city>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Levecq Jean-Marc, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie et de Radiothérapie du Parc</name>
      <address>
        <city>Chalon-sur-Saône</city>
        <zip>71100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Schipman Benjamin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Parc de Charleville-Mézières</name>
      <address>
        <city>Charleville-Mézières</city>
        <zip>08000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonveaux Eric, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLCC Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belliere-Calandry Aurélie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boutenbat Ghizlane, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peignaux Karine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Daniel Hollard</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claeys Marie-Virginie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble, Hôpital A.Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabelle - Flandin Isabelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR Metz-Thionville Hôpital de Mercy</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Quetin Philippe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Belfort-Montbéliard Site du Mittan</name>
      <address>
        <city>Montbéliard</city>
        <zip>25200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boulbair Fatiha, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grandgirard Alain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marquis Isabelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>El Hajj Labib, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guilbert Philippe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLCC Saint Etienne</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magné Nicolas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salze Pierre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Orangerie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karst Anne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massabeau Carole, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Troyes</name>
      <address>
        <city>Troyes</city>
        <zip>10000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beaumont Claudine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>VOGIN Guillaume, MD</last_name>
      <email>g.vogin@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spa care</keyword>
  <keyword>randomised controlled trial</keyword>
  <keyword>pentoxifylline/tocopherol combination</keyword>
  <keyword>late sequelae</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

